AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15461064 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 microg Alprostadil (PGE1) in 250 ml 0.9% saline over 2 hours
Number of subjects: 82
Study 15461064 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 microg Alprostadil (PGE1) in 250 ml 0.9% saline over 2 hours
Number of subjects: 82
Study 15461064 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 ml 0.9% saline solution)
Number of subjects: 82
Study 11559470 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecular medicine interventions, specific details not provided.
Number of subjects: 0
Study 9715151 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 38
Study 9715151 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 38
Study 8040490 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 107
Study 2459635 — intervention group
Group type: EXPERIMENTAL
Intervention: ORG 10172 (low-molecular-weight heparinoid)
Number of subjects: 14
Study 2459635 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 14
Study 29940904 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC-PA-China (automated telephone counselor)
Number of subjects: 210
Study 29940904 — intervention group
Group type: COMPARATOR
Intervention: Control (information pamphlet about benefits of physical activity)
Number of subjects: 210
Study 29940904 — intervention group
Group type: EXPERIMENTAL
Intervention: TLC-PA-China
Number of subjects: 210
Study 28851798 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 70
Study 28851798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 25655533 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NIPPV)
Number of subjects: 86
Study 25655533 — intervention group
Group type: EXPERIMENTAL
Intervention: NIPPV
Number of subjects: 86
Study 24265181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol (10 mg OD)
Number of subjects: 45
Study 24265181 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification (5-10% weight loss via calorie restriction and physical activity)
Number of subjects: 45
Study 24265181 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol plus lifestyle modification
Number of subjects: 45
Study 21503128 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal initial therapy (group I)
Number of subjects: 66
Study 21503128 — intervention group
Group type: EXPERIMENTAL
Intervention: Professional mechanical tooth cleaning (PMTC) (group II)
Number of subjects: 66
Study 21503128 — intervention group
Group type: COMPARATOR
Intervention: Non-clinical therapy (control group)
Number of subjects: 66
Study 17442688 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (10-400 mg)
Number of subjects: 16
Study 15196286 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg/day)
Number of subjects: 30
Study 15196286 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (5 mg/day)
Number of subjects: 30
Study 15196286 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 12220477 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral provocation tests (OPT) for paracetamol hypersensitivity
Number of subjects: 84
Study 12220477 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin eruptions
Number of subjects: 84
Study 12220477 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate reactions
Number of subjects: 84
Study 12220477 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy
Number of subjects: 84
Study 12220477 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin/ibuprofen hypersensitivity
Number of subjects: 84
Study 9635700 — intervention group
Group type: COMPARATOR
Intervention: Abdominal radiation therapy at 22.5 Gy in 22 fractions (low-dose arm)
Number of subjects: 125
Study 9635700 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal radiation therapy at 27.5 Gy in 27 fractions (high-dose arm)
Number of subjects: 125
Study 7575042 — intervention group
Group type: EXPERIMENTAL
Intervention: Different associations and galenic forms of medicines (specific details not provided)
Number of subjects: 0
Study 2521029 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP), 0.3 microgram/kg, intravenously
Number of subjects: 20
Study 2521029 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study 2521029 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP)
Number of subjects: 20
Study 2521029 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (DDAVP) and Placebo
Number of subjects: 20
Study 788737 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutiorex
Number of subjects: 6
Study 788737 — intervention group
Group type: EXPERIMENTAL
Intervention: Norflutiorex
Number of subjects: 6
Study 788737 — intervention group
Group type: COMPARATOR
Intervention: Fenfluramine
Number of subjects: 6
Study 788737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29672714 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 3 years
Number of subjects: 138
Study 29672714 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 2/3 years
Number of subjects: 138
Study 29672714 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 5 years
Number of subjects: 138
Study 29672714 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg every 6 months for 10 years
Number of subjects: 138
Study 29672714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 28893206 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood flow restriction cycling group
Number of subjects: 75
Study 28893206 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional cycling group
Number of subjects: 75
Study 28893206 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 75
Study 26445392 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini sling (Ophira)
Number of subjects: 100
Study 26445392 — intervention group
Group type: COMPARATOR
Intervention: Rectus fascia pubovaginal sling
Number of subjects: 100
Study 22906795 — intervention group
Group type: EXPERIMENTAL
Intervention: Optoelectronic plethysmography (VC-Opto)
Number of subjects: 20
Study 22906795 — intervention group
Group type: COMPARATOR
Intervention: Spirometry (VC-Spiro)
Number of subjects: 20
Study 21508007 — intervention group
Group type: EXPERIMENTAL
Intervention: Local activation times (LAT) during left atrial appendage (LAA) pacing at baseline
Number of subjects: 45
Study 21508007 — intervention group
Group type: EXPERIMENTAL
Intervention: Local activation times (LAT) during left atrial appendage (LAA) pacing at incomplete roof block
Number of subjects: 45
Study 21508007 — intervention group
Group type: EXPERIMENTAL
Intervention: Local activation times (LAT) during left atrial appendage (LAA) pacing at roof block
Number of subjects: 45
Study 21508007 — intervention group
Group type: EXPERIMENTAL
Intervention: Local activation times (LAT) during left atrial appendage (LAA) pacing at roof and mitral isthmus block
Number of subjects: 45
Study 21508007 — intervention group
Group type: EXPERIMENTAL
Intervention: LAA to high posterior wall times >133 ms
Number of subjects: 45
Study 21508007 — intervention group
Group type: EXPERIMENTAL
Intervention: High posterior wall to LAA times >125 ms
Number of subjects: 45
Study 21508007 — intervention group
Group type: EXPERIMENTAL
Intervention: Double potential >77 ms
Number of subjects: 45
Study 18296926 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IOP measurement
Number of subjects: 104
Study 18296926 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up IOP measurement
Number of subjects: 104
Study 18296926 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP comparison by ethnicity
Number of subjects: 104
Study 18296926 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP comparison by gender
Number of subjects: 104
Study 18296926 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between baseline IOP and myopic progression
Number of subjects: 104
Study 18296926 — intervention group
Group type: EXPERIMENTAL
Intervention: Association between IOP and axial length
Number of subjects: 104
Study 16929992 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mL of 2% ropivacaine hydrochloride with epinephrine
Number of subjects: 20
Study 16929992 — intervention group
Group type: COMPARATOR
Intervention: 5 mL of 0.9% saline with epinephrine (control)
Number of subjects: 20
Study 15096969 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPA (to estimate GFR)
Number of subjects: 92
Study 15096969 — intervention group
Group type: EXPERIMENTAL
Intervention: MAG3 (to produce images and curves)
Number of subjects: 92
Study 11281468 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 40 mg
Number of subjects: 66
Study 11281468 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 microg
Number of subjects: 66
Study 11281468 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (isosorbide mononitrate 40 mg and misoprostol 400 microg)
Number of subjects: 66
Study 9850360 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA-BDP 800 micrograms day-1
Number of subjects: 233
Study 9850360 — intervention group
Group type: COMPARATOR
Intervention: CFC-BDP 1500 micrograms day-1
Number of subjects: 233
Study 8008424 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolperisone HCl, a centrally acting muscle relaxant
Number of subjects: 0
Study 2520847 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 50 mcg
Number of subjects: 0
Study 2520847 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 100 mcg
Number of subjects: 0
Study 2520847 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 200 mcg
Number of subjects: 0
Study 2520847 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol 400 mcg
Number of subjects: 0
Study 2520847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2520847 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (all doses)
Number of subjects: 0
Study 2520847 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 0
Study 54273 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (3 cc administered intramuscularly within seven days after admission, repeated three months later)
Number of subjects: 0
Study 54273 — intervention group
Group type: COMPARATOR
Intervention: Conventional gammaglobulin (3 cc administered intramuscularly within seven days after admission, repeated three months later)
Number of subjects: 0
Study 31782309 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture stimulation for 10 minutes
Number of subjects: 15
Study 31782309 — intervention group
Group type: COMPARATOR
Intervention: Control (no EA stimulation)
Number of subjects: 15
Study 31603295 — intervention group
Group type: EXPERIMENTAL
Intervention: Supera + DCB
Number of subjects: 160
Study 31603295 — intervention group
Group type: COMPARATOR
Intervention: Supera
Number of subjects: 160
Study 31603295 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 160
Study 28835403 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study 26115111 — intervention group
Group type: EXPERIMENTAL
Intervention: Test condition (n = 43) - learners wrote a short test consisting of 10 short-answer questions (SAQs)
Number of subjects: 83
Study 26115111 — intervention group
Group type: COMPARATOR
Intervention: Study condition (n = 40) - learners studied the same information
Number of subjects: 83
Study 23624448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen supplementation
Number of subjects: 70
Study 23624448 — intervention group
Group type: COMPARATOR
Intervention: Room air breathing
Number of subjects: 70
Study 22224253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb (10 g by nasal feeding, 5 g L-glutamine by oral administration, three times per day)
Number of subjects: 30
Study 19615944 — intervention group
Group type: EXPERIMENTAL
Intervention: G‐CSF and AMD3100
Number of subjects: 0
Study 19615944 — intervention group
Group type: COMPARATOR
Intervention: G‐CSF
Number of subjects: 0
Study 19615944 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD3100
Number of subjects: 0
Study 19615944 — intervention group
Group type: EXPERIMENTAL
Intervention: AMD3100 mobilized grafts
Number of subjects: 0
Study 19615944 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemokine axis‐mobilized PBSC
Number of subjects: 0
Study 17091142 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin major connector analogs (MCAs)
Number of subjects: 19
Study 17091142 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide major connector analogs (MCAs)
Number of subjects: 19
Study 17091142 — intervention group
Group type: COMPARATOR
Intervention: Thick major connector analogs (MCAs)
Number of subjects: 19
Study 17091142 — intervention group
Group type: COMPARATOR
Intervention: Narrow major connector analogs (MCAs)
Number of subjects: 19
Study 14872175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentrations of MCP-1
Number of subjects: 23
Study 14872175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentrations of tumor necrosis factor-alpha
Number of subjects: 23
Study 14872175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentrations of RANTES
Number of subjects: 23
Study 14872175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentrations of MMP-9
Number of subjects: 23
Study 14872175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid (CSF) concentrations of MIP-1-alpha and MIP-1-beta
Number of subjects: 23
Study 14872175 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CSF concentrations of MCP-1 and MMP-9 from baseline to Week 48
Number of subjects: 23
Study 11320383 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (1200 mg loading dose 1 day before surgery, followed by 200 mg daily for 7 days)
Number of subjects: 315
Study 11320383 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 11320383 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (in elderly patients age >= 60 years)
Number of subjects: 315
Study 11320383 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in elderly patients age >= 60 years)
Number of subjects: 315
Study 9223880 — intervention group
Group type: EXPERIMENTAL
Intervention: Group F (fast; injection speed >= 0.2 ml.s‐1)
Number of subjects: 42
Study 9223880 — intervention group
Group type: EXPERIMENTAL
Intervention: Group M (moderate; 0.1 < injection speed < 0.2 ml.s‐1)
Number of subjects: 42
Study 9223880 — intervention group
Group type: EXPERIMENTAL
Intervention: Group S (slow; injection speed <= 0.1 ml.s‐1)
Number of subjects: 42
Study 8094648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 200 mg
Number of subjects: 20
Study 8094648 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridostigmine 120 mg
Number of subjects: 20
Study 8094648 — intervention group
Group type: EXPERIMENTAL
Intervention: GH pretreatment
Number of subjects: 20
Study 8094648 — intervention group
Group type: COMPARATOR
Intervention: GHRH alone
Number of subjects: 20
Study 3673526 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime 0.75 grams intravenously thrice daily for 24 hours (Group B)
Number of subjects: 121
Study 3673526 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime for 24 hours plus 6 days of oral cephalexin (Group A)
Number of subjects: 121
Study 30520217 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine 100 U/mL (Gla-100)
Number of subjects: 3415
Study 29024214 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracerebral insertion of stem cells
Number of subjects: 66
Study 29024214 — intervention group
Group type: COMPARATOR
Intervention: Placebo neurosurgery
Number of subjects: 66
Study 29024214 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 66
Study 26739996 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) intervention (high in MUFA)
Number of subjects: 7098
Study 26739996 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 7098
Study 26739996 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D subjects with CLOCK-rs4580704 SNP
Number of subjects: 7098
Study 24070573 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture 1 (Algeos)
Number of subjects: 46
Study 24070573 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture 2 (Crocs™)
Number of subjects: 46
Study 24070573 — intervention group
Group type: COMPARATOR
Intervention: Control (smooth insoles)
Number of subjects: 46
Study 22434665 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-carboplatin regimen
Number of subjects: 528
Study 22434665 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine-cisplatin regimen
Number of subjects: 528
Study 22434665 — intervention group
Group type: EXPERIMENTAL
Intervention: RASSF1A methylation
Number of subjects: 528
Study 22434665 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic model including RASSF1A, DAPK1, and tumor stage
Number of subjects: 528
Study 19397645 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U of botulinum toxin type A (BT‐A) reconstituted 15 days before injection
Number of subjects: 105
Study 19397645 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U of botulinum toxin type A (BT‐A) reconstituted 8 days before injection
Number of subjects: 105
Study 19397645 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 U of botulinum toxin type A (BT‐A) reconstituted 8 hours before injection
Number of subjects: 105
Study 19397645 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 105
Study 17615252 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/kg mesna
Number of subjects: 11
Study 17615252 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 11
Study 16167153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant placed after tooth separation on all enamel lesions (n=17)
Number of subjects: 50
Study 16167153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant and fluoride varnish in a split-mouth design (n=7)
Number of subjects: 50
Study 16167153 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish treatment without tooth separation (Control group, n=26)
Number of subjects: 50
Study 16167153 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish treatment (split-mouth design)
Number of subjects: 50
Study 16167153 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant groups
Number of subjects: 50
Study 16167153 — intervention group
Group type: COMPARATOR
Intervention: Fluoride varnish groups
Number of subjects: 50
Study 12119245 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained ventricular arrhythmias (VF and VT)
Number of subjects: 26416
Study 9786261 — intervention group
Group type: EXPERIMENTAL
Intervention: Color Duplex Ultrasound (CDU)
Number of subjects: 79
Study 9786261 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography (CT)
Number of subjects: 79
Study 8582152 — intervention group
Group type: EXPERIMENTAL
Intervention: Data archiving for meta-analysis
Number of subjects: 0
Study 2669571 — intervention group
Group type: EXPERIMENTAL
Intervention: Basilic vein cutdown
Number of subjects: 138
Study 2669571 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous subclavian vein placement
Number of subjects: 138
Study 788910 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydergot (2.5 mg, 3 times a day for 4 weeks)
Number of subjects: 36
Study 788910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31536654 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus in combination with mycophenolate mofetil (MMF)
Number of subjects: 587
Study 31536654 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus in combination with sirolimus
Number of subjects: 587
Study 31536654 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus-based therapy
Number of subjects: 587
Study 30958707 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated hip-focused exercise
Number of subjects: 112
Study 30958707 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional knee-focused exercise
Number of subjects: 112
Study 30958707 — intervention group
Group type: COMPARATOR
Intervention: Free physical activity
Number of subjects: 112
Study 29038901 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with adrenaline
Number of subjects: 100
Study 29038901 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 100
Study 24700335 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar fresh osteochondral allografts (BFOA)
Number of subjects: 7
Study 24242999 — intervention group
Group type: COMPARATOR
Intervention: Arterolane (RBx11160) maleate 100 mg single oral dose
Number of subjects: 64
Study 24242999 — intervention group
Group type: COMPARATOR
Intervention: Arterolane (RBx11160) maleate 25, 50, 100, 150, 200, 300, 400, 600 mg single oral doses
Number of subjects: 64
Study 24242999 — intervention group
Group type: COMPARATOR
Intervention: Arterolane (RBx11160) maleate 25, 50, 100, 200 mg multiple oral doses
Number of subjects: 64
Study 24242999 — intervention group
Group type: COMPARATOR
Intervention: Arterolane (RBx11160) maleate
Number of subjects: 64
Study 24242999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22386130 — intervention group
Group type: EXPERIMENTAL
Intervention: Psidium cattleianum leaf extract
Number of subjects: 10
Study 22386130 — intervention group
Group type: COMPARATOR
Intervention: Negative control (deionised water)
Number of subjects: 10
Study 22386130 — intervention group
Group type: COMPARATOR
Intervention: Active control (commercial mouthwash)
Number of subjects: 10
Study 19584683 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate everolimus (IE)
Number of subjects: 139
Study 19584683 — intervention group
Group type: COMPARATOR
Intervention: Delayed everolimus (DE)
Number of subjects: 139
Study 17889468 — intervention group
Group type: EXPERIMENTAL
Intervention: Atuna racemosa extract (MIC=16-32 microg/mL)
Number of subjects: 0